Rafferty Asset Management’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.5M | Sell |
196,782
-5,346
| -3% | -$231K | 0.03% | 301 |
|
|
2025
Q1 | $6.99M | Sell |
202,128
-48,114
| -19% | -$1.66M | 0.03% | 312 |
|
|
2024
Q4 | $6.87M | Buy |
250,242
+6,911
| +3% | +$190K | 0.02% | 349 |
|
|
2024
Q3 | $6.2M | Sell |
243,331
-28,276
| -10% | -$720K | 0.02% | 368 |
|
|
2024
Q2 | $6.88M | Sell |
271,607
-44,835
| -14% | -$1.14M | 0.03% | 346 |
|
|
2024
Q1 | $9.78M | Buy |
316,442
+40,369
| +15% | +$1.25M | 0.04% | 272 |
|
|
2023
Q4 | $11.1M | Sell |
276,073
-37,309
| -12% | -$1.51M | 0.05% | 247 |
|
|
2023
Q3 | $8.26M | Sell |
313,382
-205,864
| -40% | -$5.43M | 0.05% | 277 |
|
|
2023
Q2 | $8.93M | Buy |
519,246
+177,966
| +52% | +$3.06M | 0.05% | 232 |
|
|
2023
Q1 | $5.66M | Sell |
341,280
-377,989
| -53% | -$6.27M | 0.04% | 360 |
|
|
2022
Q4 | $5.48M | Buy |
719,269
+128,529
| +22% | +$979K | 0.05% | 358 |
|
|
2022
Q3 | $5.87M | Buy |
590,740
+137,660
| +30% | +$1.37M | 0.06% | 298 |
|
|
2022
Q2 | $4.11M | Sell |
453,080
-170,122
| -27% | -$1.54M | 0.04% | 317 |
|
|
2022
Q1 | $6.33M | Buy |
623,202
+477,498
| +328% | +$4.85M | 0.04% | 312 |
|
|
2021
Q4 | $2.43M | Buy |
145,704
+83,823
| +135% | +$1.4M | 0.01% | 594 |
|
|
2021
Q3 | $2.9M | Buy |
61,881
+21,078
| +52% | +$988K | 0.02% | 496 |
|
|
2021
Q2 | $2.49M | Sell |
40,803
-6,147
| -13% | -$375K | 0.02% | 606 |
|
|
2021
Q1 | $2.89M | Buy |
46,950
+31,754
| +209% | +$1.96M | 0.02% | 517 |
|
|
2020
Q4 | $1.08M | Sell |
15,196
-29,059
| -66% | -$2.07M | 0.01% | 481 |
|
|
2020
Q3 | $1.66M | Buy |
44,255
+10,946
| +33% | +$411K | 0.02% | 472 |
|
|
2020
Q2 | $1.09M | Buy |
+33,309
| New | +$1.09M | 0.02% | 519 |
|
|
2020
Q1 | – | Sell |
-19,248
| Closed | -$675K | – | 618 |
|
|
2019
Q4 | $675K | Buy |
+19,248
| New | +$675K | 0.01% | 633 |
|